This is a preview of subscription content, log in to check access.
Ueno N, et al. Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings. Japanese Journal of Clinical Oncology 49: 676-686, No. 7, Jul 2019. Available from: URL:
http://doi.org/10.1093/jjco/hyz049 - JapanCrossRefGoogle Scholar